IL127210A0 - Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use - Google Patents

Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use

Info

Publication number
IL127210A0
IL127210A0 IL12721097A IL12721097A IL127210A0 IL 127210 A0 IL127210 A0 IL 127210A0 IL 12721097 A IL12721097 A IL 12721097A IL 12721097 A IL12721097 A IL 12721097A IL 127210 A0 IL127210 A0 IL 127210A0
Authority
IL
Israel
Prior art keywords
raf
beta
proteins
binding
chain
Prior art date
Application number
IL12721097A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL127210A0 publication Critical patent/IL127210A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12721097A 1996-05-23 1997-05-22 Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use IL127210A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1818396P 1996-05-23 1996-05-23
PCT/US1997/008542 WO1997044058A1 (fr) 1996-05-23 1997-05-22 Composes inhibant la liaison de proteines raf-1 ou 14-3-3 a la chaine beta du recepteur d'il-2, et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
IL127210A0 true IL127210A0 (en) 1999-09-22

Family

ID=21786680

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12721097A IL127210A0 (en) 1996-05-23 1997-05-22 Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use

Country Status (7)

Country Link
US (1) US6281193B1 (fr)
EP (1) EP0910401A1 (fr)
JP (1) JP2000511419A (fr)
AU (1) AU728701B2 (fr)
CA (1) CA2256109A1 (fr)
IL (1) IL127210A0 (fr)
WO (1) WO1997044058A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP2009544617A (ja) * 2006-07-21 2009-12-17 ノバルティス アクチエンゲゼルシャフト ベンゾイミダゾリルピリジルエーテルの製剤
EP2074226A2 (fr) * 2006-09-19 2009-07-01 Novartis AG Biomarqueurs de modulation cible, efficacité, diagnostic et/ou pronostic pour les inhibiteurs de la raf
WO2010100127A1 (fr) 2009-03-04 2010-09-10 Novartis Ag Dérivés d'imidazole disubstitués en tant que modulateurs de la protéine kinase raf
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US9181238B2 (en) 2010-02-05 2015-11-10 Novartis Ag N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
JP2013529619A (ja) 2010-06-25 2013-07-22 ノバルティス アーゲー タンパク質キナーゼ阻害剤としてのヘテロアリール化合物および組成物
WO2013078349A1 (fr) 2011-11-23 2013-05-30 The Trustees Of Columbia University In The City Of New York Systèmes, procédés et supports permettant d'effectuer une mesure de forme
WO2022125694A1 (fr) * 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions de polypeptides d'interleukine avec des molécules de liaison à l'antigène bispécifique pour moduler la fonction de cellules immunitaires
WO2024050383A2 (fr) * 2022-08-29 2024-03-07 The Regents Of The University Of California Biocapteurs de ras

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0408790A1 (fr) * 1989-07-20 1991-01-23 Taniguchi, Tadatsugu, Dr. Récepteur protéique recombinant

Also Published As

Publication number Publication date
AU3133997A (en) 1997-12-09
US6281193B1 (en) 2001-08-28
WO1997044058A1 (fr) 1997-11-27
EP0910401A1 (fr) 1999-04-28
JP2000511419A (ja) 2000-09-05
CA2256109A1 (fr) 1997-11-27
AU728701B2 (en) 2001-01-18
US20010016194A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
IL121236A0 (en) Cycloalkano-pyridines their preparation and pharmaceutical compositions containing them
HUP0101999A3 (en) 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
IL113410A0 (en) Substituted sulfonamides their use and pharmaceutical compositions containing them
IL114622A (en) 5-membered heteroaryl-oxazolidinones and pharmaceutical compositions containing them
HUP9901874A3 (en) Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL132426A0 (en) An amyloid binding compound and pharmaceutical compositions containing the same
AP9701090A0 (en) Novel taxoids preparation thereof and pharmaceutical compositions containing same
HUP0001309A3 (en) 1-phenyl-4-benzylpiperazines and pharmaceutical compositions containing them
HUP0004398A3 (en) Alpha-aryl-n-alkylnitrones and pharmaceutical compositions containing the same
HUP9900424A2 (hu) Tiazolil-benzfurán-származékok és a vegyületeket tartalmazó gyógyászati készítmények
IL122717A0 (en) Compounds and pharmaceutical compositions containing them
IL115771A (en) Apolipoprotein-B synthesis inhibitors their preparation and pharmaceutical compositions containing them
HUP9901452A3 (en) Bicyclic-aromatic compounds and pharmaceutical compositions containing them
HUP0103896A3 (en) Oxygenic heterocyclic compounds pharmaceutical compositions containing them and their use
IL128058A0 (en) Illudin analogs and pharmaceutical compositions containing the same
IL127210A0 (en) Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
HUP0001858A3 (en) Bi-aromatic compounds and pharmaceutical and cosmetic compositions containing same and the use of the compounds
IL125998A0 (en) Taxoids preparation thereof and pharmaceutical compositions containing them
IL116101A0 (en) Benzamide its preparation and pharmaceutical compositions containing it
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
IL114623A0 (en) Substituted triazolylmethylphenylnaph-thyridones their preparation and pharmaceutical compositions containing them